A History of Alzheimer’s
disease Research
A4
ADNI
ATRI
ACTC
600 BCE
Defining Life Stages
See more
100 BCE
Differentiating Senility and Aging
See more
1906
Alzheimer’s Disease Identified
See more
1910
Naming of the Disease
See more
1974
Founding of the National Institute on Aging (NIA)
See more
1974
Establishment of the Alzheimer’s Association
See more
1975
Mini-Mental State Examination (MMSE)
See more
1976
Dr. Robert Katzman publishes: “The Prevalence and Malignancy of Alzheimer’s Disease” in The Archives of Neurology
See more
1984
Discovery of Amyloid Plaques and Neurofibrillary Tangles
See more
1986
Tau Protein Identified a Key component of Tangles
See more
1987
First Encouraging Alzheimer’s Drug Trial
See more
1988
Clinical Dementia Rating (CDR)
See more
1991
Alzheimer’s Disease Cooperative Study (ADCS) Launched
See more
1992
Duke University Links ApoE Gene to Alzheimer’s Risk
See more
1993
Tacrine Drug Trial
See more
1996
Approval of Donepezil
See more
1997
Rivastimine approved
See more
1999
Amyloid Immunization Vaccine Development
See more
2003
The Alzheimer’s Genome Project
See more
2003
Memantine is Approved
See more
2004
Nationwide Study Launched to Establish Standards for Obtaining and Interpreting Brain Images: ADNI
See more
2004
Amyloid PET Scan Development
See more
2005
NIA’s Alzheimer’s Disease Preclinical Drug Development Program is Established
See more
2005
Growth of Alzheimer’s Disease Cooperative Study (ADCS)
See more
2007
ADCS
See more
2011
Introduction of the Stages of Alzheimer’s
See more
2011
National Alzheimer’s Project Act (NAPA) Signed into Law
See more
2013
Tau PET
See more
2015
ATRI Founded as a San Diego Institute of USC
See more
2016
Focus On Lifestyle Factors
See more
2016
Alzheimer’s Clinical Consortium (ACTC) Funded and Established under the leadership of USC (Aisen) , Mayo Clinic (Petersen), and Harvard (Sperling)
See more
2016
PRIME Study Results
See more
2017
Blood Biomarkers for Early Detection
See more
2020
Advances in Early Detection
See more
2021
FDA Approved Aduhelm
See more
2021
Aducanamab receives accelerated FDA Approval in a controversial decision
See more
2022
FDA Approves Lecanemab
See more
2022
Lecanemab FDA Approval:the first full approval for a disease-modifying (slowing) therapy
See more
2023
Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer’s Disease
See more
2023
FDA Grants Full Approval to Lecanemab for the Treatment of Alzheimer’s
See more
2023
ATRI Expands Scope
See more
2023
Donanemab’s Phase 3 Success
See more
2023
Dr. Aisen Honored with Epstein Alzheimer’s Disease Director’s Chair
See more
2023
Full FDA Approval for Lecanemab
See more